Skip to main content
OpenTrials

Clinical trial condition

Esophageal Neoplasms

Explore clinical trials studying Esophageal Neoplasms. Study availability and eligibility vary by location and protocol.

304 public trials 108 recruiting studies
Refine in advanced search Browse all conditions

Esophageal Neoplasms trial results

Completed

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03430843

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +17 more
Locations
  • Henry Ford Hospital Detroit, Michigan, United States
  • Toledo Clinic Cancer Center Toledo, Ohio, United States
  • Imelda Ziekenhuis Bonheiden Bonheiden, Belgium
  • Cliniques Universitaires Saint Luc Brussels, Belgium
View all 104 locations
View Trial Details
Completed

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

NCT03469557

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +15 more
Locations
  • Fifth Medical Center of Pla General Hospital Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China
  • Northern Jiangsu Peoples Hospital Yangzhou, Jiangsu, China
View Trial Details
Completed

High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy

NCT06063941

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
Locations
  • Ankang Central Hospital Ankang, Shaanxi, China
  • Xijing Hospital of Digestive Diseases Xi'an, Shaanxi, China
  • Air Force 986 Hospital Xi'an, Shaanxi, China
  • Xi'an International Medical Center Hospital Xi'an, Shaanxi, China
View Trial Details
Completed

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

NCT04641871

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Squamous Cell, +20 more
Locations
  • University of Colorado Aurora, Colorado, United States
  • Mayo Clinic - Jacksonville Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Chicago Chicago, Illinois, United States
View all 17 locations
View Trial Details

Related conditions